Sun Zuyue, male, Ph.D, was born in Nanjing, Jiangsu province in Aug., 1964. He is a researcher of Shanghai Institution of Planned Parenthood Research, the director of National Evaluation Centre for the Toxicology of Fertility Regulating drugs (WHO collaborating centre for research in human reproduction), and a tutor of Ph.D. candidate of Fudan University. He is national outstanding scientific and technological worker, enjoying special government allowance issued by the State Council, and awarded the title of “Shanghai leading talented person” by Shanghai Municipal Organization Department of CPC, Shanghai human resources and Social Security Bureau.
       He was graduated from the Department of Health in Nanjing Medical College in July 1986  (renamed: College of public health of Nanjing Medical University ) where got the bachelor's degree of medicine;  graduated from College of Public Health of Shanghai Medical University in July 1992 (renamed: College of Public Health of Fudan University) majored in environmental toxicology where got master's degree of Medicine; and graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences majored in pharmacology and toxicology where got doctor's degree in Jan., 1997. He left Post-Doctoral Research State of Shanghai Institute of Cell Biology, Chinese Academy of Sciences  (renamed: Shanghai Institute of Biochemistry and Cell Biology Research Institute, China Chinese Academy of Sciences) majored in Cell Biology in Aug.,1999.
       He held the Councilor Member of Asian Society of Toxicology (ASIATOX), Executive Council Member of the first Board of Specialty Committee of Innovation of New Drugs of TCM of World Federation of Chinese Medicine Societies, Vice-chairman of Chinese Society of Toxicology (CST), Chairman of Reproductive Toxicology Branch of CST, Chairman of youth commission of CST, Vice-Chairman of Professional Committee of Traditional Medicine and Natural of CST, the Expert of Decision-making Consultation Expert Tank of Association for Science and Technology (CAST), the expert of Drug Evaluating (CDE) and GLP Certification of Chinese State Food and Drug Administration (CFDA), the Committee Member of China National Accreditation Board for Laboratories (CNAL),the vice-chairman of Mutagenic Professional Committee of Chinese Environmental Mutagen Society (CEMS), the Committee Member of Toxicology Branch of CSP and Editorial Committee Member of domestic academic journals more than 20 academic societies.
       Specialty: pharmacology and toxicology.  Research direction: prostate diseases pharmacological and toxicological, medicine reproductive toxicological research, and nonclinical safety evaluation on new drugs. He has taken charge of over 15 studies projects at national and ministerial level, for example, “The science and technology major specialized projects for ‘significant new drugs creation’ of 12th five-year plan”, “Introducing safety evaluation technology on new drugs of USA, to establish evaluation system in accordance with international standards”, “Establishing and perfecting technology platform for preclinical evaluation of anti-prostate disease drug”, and “Shanghai science and technology major specialized project”. 
       During 2000-2015, he hosted and finished about 258 science and technology projects such as “Establishing and perfecting technology platform for preclinical evaluation of anti-prostate disease drug” and “The preclinical study on PEG-IFN”; awarded two Science & Technology Progress Award II of Shanghai by hosting the “Study and apply on the pharmacology & toxicology of prostate hyperplasia” as the representative, one Award III, one Science & Technology Award II of Chinese Association For Laboratory Animal Sciences for “Establishment and application of the biological model of prostate diseases”, and one Science & Technology Award III of Chinese Pharmaceutical Association for “Establishment and application of non-clinical drug evaluation system against male reproductive and urinary tract disease”. He won Silver Prize at 93’ Chinese Fair of High-New Science and Technology for “Development and put into production of new disinfectant detergent”. He has submitted 24 applications for patent such as “Pessary to kill HIV and sperm in vagina” and “targeted drug for treating prostate diseases”, 17 of which authorized and 11 invention patents. He developed six science and technology products such as”Cervical cap membrane to prevent and treat cervical erosion “and” A multifunctional antiseptics, QINGJIEJING”. He has published take " The mechanism of epristeride against benign prostatic hyperplasia” and “Long-term toxicity of epristeride on Beagle Dogs" as representative's 301 papers, edited take "Prostate Pharmacology", "Drug Reproductive and Developmental Toxicology" and "The Interlocution on Prostatic Diseases" as representative's 6 academic books.